Gemzar and Microangiopathy - a phase IV clinical study of FDA data

Summary:

Microangiopathy is reported as a side effect among people who take Gemzar (gemcitabine hydrochloride), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Carboplatin, and have High blood pressure.

The phase IV clinical study analyzes which people have Microangiopathy when taking Gemzar. It is created by eHealthMe based on reports of 20,184 people who have side effects when taking Gemzar from the FDA, and is updated regularly.

What is Gemzar?

Gemzar has active ingredients of gemcitabine hydrochloride. It is often used in pancreatic carcinoma. eHealthMe is studying from 20,315 Gemzar users. Check the latest studies of Gemzar.

What is Microangiopathy?

Microangiopathy (disease of the capillaries (very small blood vessels), in which the capillary walls become so thick and weak that they bleed, leak protein) is found to be associated with 237 drugs and 331 conditions by eHealthMe. Check the latest studies of Microangiopathy.

On Jul, 28, 2026

20,184 people reported to have side effects when taking Gemzar.
Among them, 15 people (0.07%) have Microangiopathy.

Among these 15 people:

How long have people been on Gemzar when they have Microangiopathy? *

What is the gender of people who have Microangiopathy when taking Gemzar? *

female: 53.33 %
male: 46.67 %

What is the age of people who have Microangiopathy when taking Gemzar? *

What are other drugs people take besides Gemzar? *

What are other side effects people have besides Microangiopathy? *

Malignant Neoplasm Progression (cancer tumour came back): 4 people, 26.67%
Pain In Extremity: 3 people, 20.00%
Haemolysis (breaking open of red blood cells and the release of haemoglobin into the surrounding fluid): 3 people, 20.00%
Extremity Necrosis (death of body tissue of arms and legs): 3 people, 20.00%
Raynaud's Phenomenon (discoloration of the fingers, toes, and occasionally other areas): 3 people, 20.00%
Blood Creatinine Increased: 2 people, 13.33%
Necrosis (the death of body tissue): 2 people, 13.33%
Oedema Peripheral (superficial swelling): 2 people, 13.33%
Pain: 2 people, 13.33%
High Blood Pressure: 2 people, 13.33%

What are the existing conditions these people have? *

High Blood Pressure: 3 people, 20.00%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 2 people, 13.33%
Diabetes: 2 people, 13.33%
Bladder Cancer: 2 people, 13.33%
Adenocarcinoma Pancreas (cancer of pancreas): 2 people, 13.33%
Sleep Disorder: 1 person, 6.67%
Ovarian Cancer (cancer of ovary): 1 person, 6.67%
Nausea (feeling of having an urge to vomit): 1 person, 6.67%
Muscle Spasms (muscle contraction): 1 person, 6.67%
Lung Cancer - Non-Small Cell (lung cancer): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Gemzar and have Microangiopathy?

- Check whether Microangiopathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Gemzar:

Gemzar (20,315 reports)

Microangiopathy treatments and more:

Microangiopathy (1,304 reports)

Browse all side effects of Gemzar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Microangiopathy:

Microangiopathy (237 drugs)

Browse all the conditions that are associated with Microangiopathy:

Microangiopathy (331 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on gemcitabine hydrochloride (the active ingredients of Gemzar) and Gemzar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.